Aging-related matrix metallopeptidase 10 and osteopontin levels are associated with pathology, cognitive decline, and age at onset in Alzheimer's disease
Two new brain fluid proteins help distinguish Alzheimer's disease patterns and track cognitive decline alongside traditional markers.
In 137 participants from a UCL dementia cohort, CSF MMP-10 and osteopontin emerged as novel aging-related biomarkers with distinct associations with Alzheimer's disease—MMP-10 linked to cognitive trajectory and age of onset, OPN to amyloid/tau burden. These biomarkers show complementary diagnostic utility alongside established AD markers.
What the study was
- Study design
- Cross-sectional biomarker study
- Population
- UCL Dementia Research Centre participants: 37 NDC, 67 AD, 33 non-AD neurodegeneration
- Sample size
- 137
- Category
- Diagnostics
- Maturity
- Exploratory
- Journal
- Alzheimer's & Dementia
Why it surfaced
Alz & Dementia (Zetterberg group, UCL); novel aging biomarkers MMP-10/OPN improve AD differentiation; validates biomarker panel concept in well-characterized cohort.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.